Icu Medical SEC Filings

ICU Medical (ICUI) Form 4: Director Elisha W. Finney exercised 1,285 non-qualified stock options at $103.76 and, on the same day (11/11/2025), sold 1,285 shares at $140.42. Following these transactions, she directly owns 3,995 shares.

The option carried a $103.76 exercise price, became exercisable on 06/15/2016, and expires on 01/08/2026; derivative securities beneficially owned after the transactions were 0.

ICU Medical (ICUI) disclosed a Form 4 reporting an insider sale by officer Virginia Sanzone, VP and General Counsel. She sold 930 shares of common stock on 11/11/2025 at $142.345 per share, coded “S” for sale. Following the transaction, she beneficially owns 5,456 shares, held directly. The filing notes all shares were sold at the exact price disclosed.

ICU Medical (ICUI) reported Q3 2025 results. Revenue was $536.99 million versus $589.13 million last year, with gross profit of $200.88 million. Operating income reached $13.72 million, but the company posted a net loss of $3.40 million (basic and diluted EPS -$0.14) as interest expense offset operating gains.

Year-to-date, revenue was $1.69 billion and net income $16.47 million, aided by a $44.79 million gain on sale of business tied to divesting a 60% stake in the IV Solutions business to OPF for $211.19 million cash and retaining a 40% equity-method interest. The retained interest was recorded at fair value and equity income was $1.30 million for the nine months (Q3 equity loss $1.54 million).

Cash and equivalents were $299.73 million, and long‑term debt declined to $1.31 billion from $1.53 billion at year‑end. Segment revenue mix in Q3: Consumables $285.09 million, Infusion Systems $173.91 million, and Vital Care $77.99 million. U.S. revenue was $307.13 million. Shares outstanding were 24,686,660 as of October 31, 2025.

ICU Medical, Inc. (ICUI) filed a Form 8-K to report that it furnished a press release announcing its financial results for the third quarter of 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition). The filing lists ICU Medical’s common stock on the Nasdaq Global Select Market under the symbol ICUI. This 8-K serves to make the company’s Q3 2025 results announcement available to the market via the furnished exhibit.

Vivek Jain, Chairman and CEO of ICU Medical, reported a Form 4 disclosing transactions dated 09/12/2025. The filing shows a gift of 63,641 shares of common stock to two trusts established for family members who share the same household; the reporting person disclaims beneficial ownership of the shares held by those trusts. After the reported transactions, Mr. Jain retained 66,508 shares directly and the trusts hold 152,339 shares indirectly. The form was signed by an attorney-in-fact on 09/15/2025.

David C. Greenberg, a director of ICU Medical, Inc. (ICUI), reported open-market purchases on 08/27/2025. The Form 4 shows two non-derivative purchases: 602 shares at a weighted-average price of $126.1428, bringing his direct beneficial ownership to 7,362 shares, and 598 shares at a weighted-average price of $126.6895, bringing his direct beneficial ownership to 7,960 shares. The filing also discloses 500 shares held indirectly by a trust. The purchases were executed in multiple transactions within the disclosed price ranges; the filer offers to provide detailed per-transaction pricing on request.

Vivek Jain, Chairman and CEO of ICU Medical, Inc. (ICUI), reported purchases of company common stock on 08/14/2025. He acquired 2,378 shares at a weighted-average price of $112.1165 (purchases ranged $111.75–$112.435) and 19,551 shares at a weighted-average price of $112.9232 (purchases ranged $112.48–$113.435). Following these transactions, Mr. Jain beneficially owns 130,149 shares directly and 88,698 shares indirectly through a trust; a prior direct holding of 110,598 shares is shown prior to the second reported purchase line. The Form 4 was signed by an attorney-in-fact, Paula Darbyshire.

Janus Henderson Group plc and an affiliated fund reported beneficial ownership stakes in ICU Medical, Inc. Janus Henderson Group plc is shown with shared voting and dispositive power over 2,470,146 common shares, equal to 10.0% of the class. Janus Henderson Enterprise Fund reports shared voting and dispositive power over 1,230,753 shares, equal to 5.0% of the class. The filing also notes that JHIUS may be deemed beneficial owner of 2,411,637 shares ( 9.8% ) with shared voting and dispositive authority.

The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. Power of attorney and signature attestations are included, identifying the compliance officer who signed on behalf of the reporting entities.

ICU Medical registered 2,150,000 shares of its common stock for issuance under the Third Amendment to its Amended and Restated 2011 Stock Incentive Plan, approved by stockholders at the 2025 annual meeting on May 13, 2025. The filing confirms these additional shares are the same class as prior awards and incorporates earlier Form S-8 and 10-K registrations by reference, and includes related exhibits and legal opinions.